PaxMedica is a clinical-stage biopharmaceutical company focused on developing innovative treatments for unmet needs in neurodevelopmental disorders. Our lead programs are focused on Autism Spectrum Disorder (ASD). There are no FDA-approved treatments for the core symptoms of ASD. As the only publicly traded US company focused exclusively on Autism, we are on a promising path to change that.
We are continuing to pursue opportunities to license or acquire additional late-stage assets and are dedicated to collaborating with companies, academia, patient advocacy groups, and other industry stakeholders worldwide. If you are interested in a partnership with PaxMedica, please contact us at firstname.lastname@example.org.
If you are interested in following our progress or learning more about our clinical trials, please complete the contact form.
PaxMedica is a proud partner of:
Supporting translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with autism.